Thalassemia: an overview of 50 years of clinical research.

The thalassemias are attributable to the defective production of the α- and β-globin polypeptides of hemoglobin. Significant discoveries have illuminated the pathophysiology and enhanced the prevention and treatment of the thalassemias, and this article reviews many of the advances that have occurred in the past 50 years. However, the application of new approaches to the treatment of these disorders has been slow, particularly in the developing world where the diseases are common, but there is definite progress. This article emphasizes how the increasing knowledge of cellular and molecular biology are facilitating the development of more effective therapies for these patients.

[1]  E. Sariban,et al.  Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity , 1995, British journal of haematology.

[2]  W. Anderson,et al.  Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .

[3]  C. Bordignon.  Stem-cell therapies for blood diseases , 2006, Nature.

[4]  R. Grady,et al.  Chelation therapy in beta-thalassemia: an optimistic update. , 2001, Seminars in hematology.

[5]  D. Nathan,et al.  Hemoglobin F and beta thalassemia. , 1967, Science.

[6]  R. Williamson,et al.  The severe form of alpha thalassaemia is caused by a haemoglobin gene deletion. , 1974, Nature.

[7]  W. Anderson,et al.  Isolation and translation of hemoglobin messenger RNA from thalassemia, sickle cell anemia, and normal human reticulocytes. , 1971, The Journal of clinical investigation.

[8]  N. Olivieri.  The β-Thalassemias , 1999 .

[9]  Gonçalo R. Abecasis,et al.  Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia , 2008, Proceedings of the National Academy of Sciences.

[10]  J. Hirschhorn,et al.  DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease , 2008, Proceedings of the National Academy of Sciences.

[11]  D. Nathan.  Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. , 1985, Progress in clinical and biological research.

[12]  S. Antonarakis,et al.  Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Brown,et al.  The clinical investigator: bewitched, bothered, and bewildered--but still beloved. , 1997, The Journal of clinical investigation.

[14]  G. Stamatoyannopoulos,et al.  Induction of human γ globin gene expression by histone deacetylase inhibitors , 2004 .

[15]  B. Forget,et al.  Defect in messenger RNA for human hemoglobin synthesis in beta thalassemia. , 1971, The Journal of clinical investigation.

[16]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[17]  S. Orkin,et al.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.

[18]  I. Wolman.  Transfusion Therapy in Cooley's Anemia: Growth and Health as Related to Long‐Range Hemoglobin Levels. A Progress Report , 1964, Annals of the New York Academy of Sciences.

[19]  N. Olivieri.  The beta-thalassemias. , 1999, The New England journal of medicine.

[20]  M. Pirastu,et al.  Clinical Research Update: Thalassemias in Sardinia Molecular Pathology, Phenotype‐Genotype Correlation, and Prevention , 1991, The American journal of pediatric hematology/oncology.

[21]  S. Brusilow,et al.  Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. , 1994, Blood.

[22]  S. Rivella,et al.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. , 2000, Nature.

[23]  R. Nagel,et al.  Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[25]  H. Varmus,et al.  Genetic lesion in homozygous alpha thalassaemia (hydrops fetalis). , 1974, Nature.

[26]  D. Nathan,et al.  New developments in iron chelators , 2005, Current opinion in hematology.

[27]  D. Jamison,et al.  Inherited Disorders of Hemoglobin -- Disease Control Priorities in Developing Countries , 2006 .

[28]  K. McIntyre,et al.  Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. , 1984, The New England journal of medicine.

[29]  T. Ley,et al.  5-AZACYTIDINE FOR BETA-THALASSAEMIA? , 1983, The Lancet.

[30]  S. Goh,et al.  High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.

[31]  S. Orkin,et al.  Transcriptional regulation of erythropoiesis: an affair involving multiple partners , 2002, Oncogene.

[32]  E. Benz.  Clinical management of gene expression. , 1982, The New England journal of medicine.

[33]  J. Clegg,et al.  Haemoglobin synthesis in beta-thalassaemia. , 1968, Nature.

[34]  B. Thorell,et al.  ABSORPTION SPECTRA OF INCLUSION BODIES IN BETA-THALASSEMIA. , 1965, Blood.

[35]  Michel Sadelain,et al.  Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.

[36]  R. Galanello,et al.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.

[37]  Charles B. Hall,et al.  Transferrin therapy ameliorates disease in β-thalassemic mice , 2010, Nature Medicine.

[38]  P. Marks,et al.  A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease , 2007, British journal of haematology.

[39]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[40]  P. Leboulch,et al.  A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. , 2005, Annals of the New York Academy of Sciences.

[41]  Y. Kan,et al.  Prenatal diagnosis of homozygous β-thalassæmia , 1975, The Lancet.

[42]  T. Maniatis,et al.  Molecular cloning and characterization of the human beta-like globin gene cluster. , 1980, Cell.

[43]  D. J. Weatherall,et al.  Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemias , 2001, Nature Reviews Genetics.

[44]  J. Clegg,et al.  Haemoglobin Synthesis in α-Thalassaemia (Haemoglobin H Disease) , 1967, Nature.

[45]  T. Maniatis,et al.  Molecular cloning and characterization of the human β-like globin gene cluster , 1980, Cell.

[46]  F. Barton,et al.  Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. , 1995, Controlled clinical trials.

[47]  Yusuke Nakamura,et al.  A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E , 2009, Human Genetics.

[48]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[49]  Serena Sanna,et al.  Amelioration of Sardinian beta0 thalassemia by genetic modifiers. , 2009, Blood.

[50]  P. Marks,et al.  Decreased globin messenger RNA in thalassemia detected by molecular hybridization. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Clegg,et al.  Globin Synthesis in Thalassaemia: An in vitro Study , 1965, Nature.

[52]  David A. Williams,et al.  Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse , 1984, Nature.

[53]  Y. Kan,et al.  Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. D. Heywood,et al.  Amino Acids: Incorporation into α- and β-Chains of Hemoglobin by Normal and Thalassemic Reticulocytes , 1964, Science.

[55]  C. Hershko,et al.  Heart cells in culture: a model of myocardial iron overload and chelation. , 1985, The Journal of laboratory and clinical medicine.

[56]  P. Marks,et al.  Hemoglobin synthesis in thalassemia. , 1971, Series haematologica.

[57]  S. Rivella,et al.  A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. , 2003, Blood.

[58]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[59]  F. Locatelli.  Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. , 2006, Hematology. American Society of Hematology. Education Program.

[60]  E. Bakker,et al.  Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. , 2004, Haematologica.

[61]  S. Orkin,et al.  Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. , 1982, Nature.

[62]  S. Rivella,et al.  Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. , 2002, Blood.

[63]  K. McIntyre,et al.  Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. , 1985, The Journal of clinical investigation.

[64]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[65]  M. Andreani,et al.  Bone Marrow Transplantation in Adults with Thalassemia: Treatment and Long‐Term Follow‐Up , 2005, Annals of the New York Academy of Sciences.

[66]  Vip Viprakasit,et al.  A Regulatory SNP Causes a Human Genetic Disease by Creating a New Transcriptional Promoter , 2006, Science.

[67]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[68]  D. Housman,et al.  Quantitative deficiency of chain-specific globin messenger ribonucleic acids in the thalassemia syndromes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[69]  G. Stamatoyannopoulos,et al.  Induction of human gamma globin gene expression by histone deacetylase inhibitors. , 2004, Blood.

[70]  J. Clegg,et al.  Haemoglobin Synthesis in β-Thalassaemia , 1968, Nature.

[71]  M. Cappellini,et al.  Oral iron chelators. , 2009, Annual review of medicine.

[72]  5—Azacytidine selectively increases globin synthesis in a patient with thalassemia , 1983 .

[73]  P. Rebulla.  Blood transfusion in beta thalassaemia major , 1995, Transfusion medicine.

[74]  R. Grady,et al.  Chelation therapy in β-thalassemia: An optimistic update☆ , 2001 .

[75]  A. Schechter,et al.  5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. , 1983, Blood.

[76]  J. Hirschhorn,et al.  Supporting Online Material Materials and Methods Figs. S1 to S10 Tables S1 to S7 References Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-specific Repressor Bcl11a , 2022 .

[77]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[78]  D. Faller,et al.  Delay in the fetal globin switch in infants of diabetic mothers. , 1985, The New England journal of medicine.

[79]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[80]  D. Weatherall,et al.  CHELATION REGIMENS WITH DESFERRIOXAMINE , 1977, The Lancet.

[81]  S. Rivella,et al.  Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene , 2002 .

[82]  W. Bodmer,et al.  5-AZACYTIDINE FOR BETA-THALASSAEMIA? , 1983, The Lancet.

[83]  S. J. Chen,et al.  Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[84]  P. Chiusolo,et al.  Reliability of leukostasis grading score to identify patients with high‐risk hyperleukocytosis , 2009, American journal of hematology.

[85]  B. Thorell,et al.  Brief Report: Absorption Spectra of Inclusion Bodies in β-Thalassemia , 1965 .

[86]  Y. Kan,et al.  Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. , 1970, The Journal of clinical investigation.

[87]  J. Tripp,et al.  Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.

[88]  P. Vossough,et al.  Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening , 2004, Annals of Hematology.

[89]  A. Bank.  Regulation of human fetal hemoglobin: new players, new complexities. , 2006, Blood.

[90]  D. Weatherall.  History of genetic disease: Thalassaemia: the long road from bedside to genome , 2004, Nature Reviews Genetics.

[91]  J. Hobbins,et al.  In utero diagnosis of: hemoglobinopathies. Hemoglobin synthesis in fetal red cells. , 1974, The New England journal of medicine.

[92]  Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. , 1982, Investigative radiology.

[93]  S. Orkin,et al.  Linkage of β-thalassaemia mutations and β-globin gene polymorphisms with DNA polymorphisms in human β-globin gene cluster , 1982, Nature.

[94]  D. Nathan.  Thalassemia: The Continued Challenge , 2005 .

[95]  Y. Kan,et al.  Successful application of prenatal diagnosis in a pregnancy at risk for homozygous beta-thalassemia. , 1975, The New England journal of medicine.

[96]  S. Orkin,et al.  Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[97]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[98]  Stuart H. Orkin,et al.  Developmental and species-divergent globin switching are driven by BCL11A , 2009, Nature.

[99]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[100]  A. Stretton,et al.  Genetic basis of the thalassaemia diseases. , 1959, Nature.

[101]  D. Zwiers,et al.  5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[102]  H. Lazarus,et al.  The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. , 1979, Cell.

[103]  M. Becker,et al.  PREVENTION OF BONE MALFORMATIONS AND CARDIOMEGALY IN COOLEY'S ANEMIA BY EARLY HYPERTRANSFUSION REGIMEN * , 1969, Annals of the New York Academy of Sciences.

[104]  D. Sonakul,et al.  Cardiac pathology in 76 thalassemic patients. , 1988, Birth defects original article series.

[105]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[106]  E. Rachmilewitz,et al.  MEDICAL PROGRESS : β-thalassemia , 2005 .

[107]  O. Platt,et al.  Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.

[108]  D. Nathan,et al.  New approaches to the transfusion management of thalassemia. , 1980, Blood.

[109]  P. Fessas.  Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. , 1963, Blood.

[110]  J. Hobbins,et al.  In utero diagnosis of hemoglobinopathies. Technic for obtaining fetal blood. , 1974, The New England journal of medicine.

[111]  P. Musgrove,et al.  Inherited Disorders of Hemoglobin , 2006 .

[112]  E. Neufeld.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. , 2006, Blood.

[113]  E. Neufeld,et al.  Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial , 2003, The Lancet.

[114]  S. Antonarakis,et al.  Prenatal diagnosis using DNA polymorphisms. Report on 95 pregnancies at risk for sickle-cell disease or beta-thalassemia. , 1983, The New England journal of medicine.

[115]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[116]  J. B. Clegg,et al.  The thalassaemia syndromes , 1965 .

[117]  Y. Kan,et al.  Prenatal diagnosis of homozygous beta-thalassaemia. , 1975, Lancet.

[118]  H. Lodish,et al.  Beta thalassemia and translation of globin messenger RNA. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[119]  S. Shurin,et al.  Reassessment of the use of desferrioxamine B in iron overload. , 1976, The New England journal of medicine.

[120]  H. Lazarus,et al.  Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. , 1978, The New England journal of medicine.

[121]  D. Faller,et al.  Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. , 1994, The American journal of pediatric hematology/oncology.

[122]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[123]  Shinya Yamanaka,et al.  Induced pluripotent stem cells and reprogramming: seeing the science through the hype , 2009, Nature Reviews Genetics.

[124]  P. Fessas.  Inclusions of Hemoglobin in Erythroblasts and Erythrocytes of Thalassemia , 1963 .

[125]  Simon Heath,et al.  A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15 , 2007, Nature Genetics.

[126]  D J Pennell,et al.  Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major , 2009, Circulation.

[127]  R. Ljung,et al.  HIGH-DOSE INTRAVENOUS GAMMABLOBULIN: A CAUTIONARY NOTE , 1985, The Lancet.

[128]  D. Samid,et al.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.

[129]  H. Lazarus,et al.  The molecular basis of α-thalassemias: Frequent occurrence of dysfunctional α loci among non-Asians with Hb H disease , 1979, Cell.

[130]  D. Higgs.  Gene regulation in hematopoiesis: new lessons from thalassemia. , 2004, Hematology. American Society of Hematology. Education Program.

[131]  S. Woo.  Policy statement of the American Society of Gene Therapy on reporting of patient adverse events in gene therapy trials. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[132]  N. Olivieri,et al.  Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. , 1995, The New England journal of medicine.

[133]  Yi Fang Liu,et al.  Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. , 2006, Blood.

[134]  P. Marks,et al.  Hemoglobins A and F: Formation in Thalassemia and Other Hemolytic Anemias , 1964, Science.

[135]  Jonathan D. Powell,et al.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. , 2009, The New England journal of medicine.

[136]  Swee Lay Thein,et al.  Molecular therapies in β‐thalassaemia , 2007, British journal of haematology.

[137]  G. Daley.  Stem cells: roadmap to the clinic. , 2010, The Journal of clinical investigation.

[138]  M. Sadelain,et al.  Current status of globin gene therapy for the treatment of β‐thalassaemia , 2008, British journal of haematology.

[139]  R. Gunn,et al.  Thalassemia: the consequences of unbalanced hemoglobin synthesis. , 1966, The American journal of medicine.

[140]  D. Loukopoulos,et al.  DISCUSSION PAPER PRENATAL DIAGNOSIS OF THALASSEMIA MAJOR IN GREECE: EVALUATION OF THE FIRST LARGE SERIES OF ATTEMPTS * , 1980, Annals of the New York Academy of Sciences.

[141]  D. Mohanty,et al.  Carrier screening for beta-thalassemia during pregnancy in India: a 7-year evaluation. , 2008, Genetic testing.

[142]  Y. Kan,et al.  Organization of the alpha-globin genes in the Chinese alpha-thalassemia syndromes. , 1979, The Journal of clinical investigation.

[143]  M. Chandy.  Stem cell transplantation in India , 2008, Bone Marrow Transplantation.

[144]  A. Hoffbrand,et al.  Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.

[145]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[146]  M. Sutton,et al.  Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. , 2007, Blood.

[147]  D. Weatherall,et al.  FIRST-TRIMESTER FETAL DIAGNOSIS FOR HAEMOGLOBINOPATHIES: THREE CASES , 1982, The Lancet.

[148]  G. Stamatoyannopoulos.  Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.

[149]  D. Nathan.  The several Cs of translational clinical research. , 2005, The Journal of clinical investigation.

[150]  D. Weatherall,et al.  Haemoglobin E beta thalassaemia in Sri Lanka. , 2005, Lancet.

[151]  P. Leboulch,et al.  A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia , 2005 .

[152]  G. Stamatoyannopoulos,et al.  Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. , 1984, Science.

[153]  T. Ganz,et al.  The Role of Hepcidin in Iron Metabolism , 2009, Acta Haematologica.

[154]  Tomas Ganz,et al.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. , 2003, Blood.

[155]  David Baltimore,et al.  Chimeric Nucleases Stimulate Gene Targeting in Human Cells , 2003, Science.

[156]  H. Bard,et al.  Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. , 1985, Pediatrics.